Table 2.
Graph measure | NC (n = 35) | BCC − (n = 32) | BCC + (n = 34) | p | |
---|---|---|---|---|---|
Cp | T1 | 0.993 ± 0.002 | 0.992 ± 0.002 | 0.992 ± 0.002 | 0.996 |
T2 | 0.994 ± 0.003 | 0.993 ± 0.003 | 0.993 ± 0.003 | 0.285 | |
Lp | T1 | 1.218 ± 0.044 | 1.226 ± 0.043 | 1.213 ± 0.035 | 0.411 |
T2 | 1.196 ± 0.044 | 1.211 ± 0.037 | 1.209 ± 0.038 | 0.207 | |
Eloc | T1 | 0.986 ± 0.003 | 0.985 ± 0.002 | 0.986 ± 0.003 | 0.151 |
T2 | 0.988 ± 0.003 | 0.984 ± 0.003 | 0.986 ± 0.003 | 0.031 | |
Eglob | T1 | 0.867 ± 0.024 | 0.862 ± 0.021 | 0.871 ± 0.018 | 0.241 |
T2 | 0.880 ± 0.025 | 0.871 ± 0.019 | 0.871 ± 0.020 | 0.477 |
BCC − breast cancer patients with no chemotherapy, BCC + breast cancer patients receiving chemotherapy, NC non-cancer controls, Cp clustering coefficient, Lp characteristic path length, Eloc local efficiency, Eglob global efficiency
Values represent mean ± SD. Values were calculated after each participants’ network was normalized with random networks
Significance was declared by p < 0.05 and significant differences are highlighted in bold